March 29, 2018 / 8:30 PM / a month ago

BRIEF-Reata Announces That Kyowa Hakko Kirin Received Sakigake Priority Review Designation For Bardoxolone Methyl In Japan

March 29 (Reuters) - Reata Pharmaceuticals Inc:

* REATA ANNOUNCES THAT KYOWA HAKKO KIRIN RECEIVED SAKIGAKE PRIORITY REVIEW DESIGNATION FOR BARDOXOLONE METHYL IN JAPAN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below